Loading patent…
AssigneesInstitut National de la Sante et de la Recherche Medicale, Universite De Rouen Normandie
InventorsSahil ADRIOUCHI, Theo LEMARCIS, Virginie TARDIF SAN MARTIN
Estimating the term…
Co-signaling immunotherapy, via immune checkpoint inhibitors (ICIs), such as ipilimumab (anti-CTLA-4) or nivolumab (anti-PD-1), has revolutionized cancer treatment. However, reinvigorating tumor-infiltrating T cell cytotoxicity has revealed cardiac toxicity in a subset of patients. The inventors found lower transcriptomic expression of CTLA-4 in eccentric hypertrophic cardiomyopathy model, associated with higher cardiac total IgG amount and less B cell infiltration, compared to concentric hypertrophic cardiomyopathy. The present invention relates to a method of treating dilated cardiomyopathy (DCM) in a subject in need thereof comprising a step of administering to said subject a therapeutically effective amount of a cytotoxic T-lymphocyte-associated protein (CTLA-4) molecule.
A method of treating dilated cardiomyopathy (DCM) in a subject in need thereof comprising a step of administering to said subject a therapeutically effective amount of a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) molecule.
A method for modulating cardiac remodeling in a subject in need thereof comprising a step of administering to said subject a therapeutically effective amount of a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) molecule.
A pharmaceutical composition comprising a molecule of CTLA-4.
A method of screening a drug suitable for treating dilated cardiomyopathy (DCM) comprising i) providing a test compound and ii) determining the ability of said test compound to activate the expression or activity of CTLA-4.
Dependencies are inferred from the claim text.